SNPMiner Trials (Home Page)
Report for SNP rs1695
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study
This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.
NCT00515216 Stomach Neoplasms Esophageal Neoplasms Drug: 5-fluorouracil Drug: Oxaliplatin Drug: Leucovorin MeSH:Stomach Neoplasms Esophageal Neoplasms Neoplasms
HPO:Esophageal neoplasm Neoplasm Neoplasm of the stomach
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response.. Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response).
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease.. Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease).
Primary Outcomes
Description: ORR = complete response + partial response Complete response - disappearance of all target and non-target lesions Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter
Measure: Overall Response Rate (ORR) Time: 2 yearsSecondary Outcomes
Measure: Overall Survival Time: 4 yearsDescription: Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
Measure: Progression-free Survival (PFS) Time: 4 yearsDescription: DCR - complete response, partial response, and stable disease Complete response - disappearance of all target and non-target lesions Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease
Measure: Disease Control Rate (DCR) Time: 2 yearsMeasure: Tumor Specific Changes That May Alter Treatment Outcomes Time: 4 years
Description: This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had a partial tumor response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had a partial tumor response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had a partial response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had a partial response.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response) Time: 4 yearsDescription: This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 yearsDescription: This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had stable disease.
Measure: Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease) Time: 4 years2 Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation
The correlation between Busulfan Pharmacokinetics in AML transplanted patients and their GST (A1,T1,M1 and P1), MDR-1 genetic profile. If a pre-genetic testing of those genes can be utilized as biomarkers of SOS and/or HGVHD. This study is not an interventional study it is only checking the GST gene and MDR-1 gene
NCT01608204 Acute Myeloid Leukemia MeSH:Leukemia, Myeloid Leukemia, Myeloid, Acute
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Myeloid leukemia
If individuals diagnosed with AML carrying the GSTP1 variant allele rs1695 (heterozygotes) are at risk of developing supra-therapeutic BU AUC due to lower BU clearance, and if combined polymorphisms in GSTM1 and ABCB1 (3435 or 2677) are associated with BU clearance rates and AUC.. Inclusion Criteria: - Acute Myeloid Leukemia who are clinically selected for HSCT according to known protocols.
Primary Outcomes
Description: If individuals diagnosed with AML carrying the GSTP1 variant allele rs1695 (heterozygotes) are at risk of developing supra-therapeutic BU AUC due to lower BU clearance, and if combined polymorphisms in GSTM1 and ABCB1 (3435 or 2677) are associated with BU clearance rates and AUC.
Measure: If GST and ABCB1 genes modify busulfan pharmacokinetics in AML patients who will be transplanted Time: end of BMT transplantation